Skip to main content
Advertisement
Main content starts here
No access
Perspective
Cell Biology

Fetal bovine serum—a cell culture dilemma

Ethical and possible reproducibility issues arise when using fetal bovine serum in cell culture media
Science
13 Jan 2022
Vol 375, Issue 6577
pp. 143-144

Abstract

Fetal bovine serum [FBS, also known as fetal calf serum (FCS)] is a popular supplement to the basal medium used in cell and tissue culture. FBS is sourced from unborn calves at the slaughterhouse, raising ethical concerns about animal welfare. Recently, two different laboratories performed in vitro experiments that applied an identical experimental procedure and used cells and FBS from the same suppliers (1). The results they obtained were very different. Further analyses revealed that one cause for the difference in cell response was the supplementation of the cell culture medium with FBS, which had originated from different batches. Given the ubiquitous use of cell culture throughout research, it is important to ensure reproducibility as well as ethical sourcing of research products, such as the development of synthetic media.

Access the full article

View all access options to continue reading this article.

References and Notes

1
H. Barosova et al., Toxicol. In Vitro 75, 105178 (2021).
2
R. G. Harrison, M. J. Greenman, F. P. Mall, C. M. Jackson, Anat. Rec. 1, 116 (1907).
3
T. T. Puck, S. J. Cieciura, A. Robinson, J. Exp. Med. 108, 945 (1958).
4
OECD, “Guidance document on Good In Vitro Method Practices (GIVIMP) for the development and implementation of in vitro methods for regulatory use in human safety assessment” (OECD, 2017); www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_Safety_Assessment.pdf.
5
US Department of Health and Human Services (HHS), Food and Drug Administration, Center for Biologics Evaluation and Research, “Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications” (HHS, 2010); www.fda.gov/media/78428/download.
6
EMA, “Guideline on the use of bovine serum in the manufacture of human biological medicinal products” (EMA, 2013); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500143930.pdf.
7
N. Bryan, K. D. Andrews, M. J. Loughran, N. P. Rhodes, J. A. Hunt, Biosci. Rep. 31, 199 (2011).
8
K. Bieback, B. Fernandez-Muñoz, S. Pati, R. Schäfer, Cytotherapy 21, 911 (2019).
9
K. Landauer, in Animal Cell Biotechnology (Springer, 2014), pp. 89–103.
10
J. van der Valk et al., Toxicol. In Vitro 24, 1053 (2010).
11
M. S. Sinacore, D. Drapeau, S. R. Adamson, Mol. Biotechnol. 15, 249 (2000).
12
M. Cimino, R. M. Gonçalves, C. C. Barrias, M. C. L. Martins, Stem Cells Int. 2017, 6597815 (2017).
13
C. Oleaga et al., Adv. Funct. Mater. 29, 1805792 (2018).
14
A. J. Lau, T. K. Chang, Toxicol. Appl. Pharmacol. 277, 221 (2014).
15
Z. Wei, A. O. Batagov, D. R. F. Carter, A. M. Krichevsky, Sci. Rep. 6, 31175 (2016).

(0)eLetters

eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Neither embedded figures nor equations with special characters can be submitted, and we discourage the use of figures and equations within eLetters in general. If a figure or equation is essential, please include within the text of the eLetter a link to the figure, equation, or full text with special characters at a public repository with versioning, such as Zenodo. Please read our Terms of Service before submitting an eLetter.

Log In to Submit a Response

No eLetters have been published for this article yet.

ScienceAdviser

Get Science’s award-winning newsletter with the latest news, commentary, and research, free to your inbox daily.